Divisadero Street Capital Management LP Sells 385,116 Shares of Bioventus Inc. $BVS

Key Points

• Divisadero Street Capital cut its stake in Bioventus by 35.6%, selling 385,116 shares and retaining 695,517 shares (about 0.84% of the company) valued at ~$4.65 million; overall institutional ownership is ~62.9%.
• Wall Street sentiment is positive with a consensus "Buy" rating and an average target price of $14.25, alongside recent upgrades (Craig Hallum to $16, Barrington to $14, and Cantor Fitzgerald to "strong‑buy").
• Insider Director Michelle Mcmurry‑Heath sold 12,000 shares at $8.79 (a 21.1% reduction in her holding); Bioventus beat Q results with $0.24 EPS on $157.9M revenue and set FY‑2026 guidance of $0.73–$0.77 EPS, with the stock trading near $8.62 (market cap ~$717M).

Divisadero Street Capital Management LP lessened its position in Bioventus Inc. (NASDAQ:BVS - Free Report) by 35.6% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 695,517 shares of the company's stock after selling 385,116 shares during the quarter. Divisadero Street Capital Management LP owned approximately 0.84% of Bioventus worth $4,653,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. PharVision Advisers LLC bought a new position in Bioventus in the second quarter worth $67,000. Covestor Ltd boosted its holdings in shares of Bioventus by 28.0% during the 3rd quarter. Covestor Ltd now owns 9,951 shares of the company's stock valued at $67,000 after buying an additional 2,176 shares in the last quarter. HB Wealth Management LLC purchased a new stake in shares of Bioventus in the 3rd quarter worth about $72,000. Olympiad Research LP purchased a new stake in shares of Bioventus in the 3rd quarter worth about $74,000. Finally, Police & Firemen s Retirement System of New Jersey increased its stake in shares of Bioventus by 55.9% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 11,768 shares of the company's stock worth $78,000 after acquiring an additional 4,221 shares in the last quarter. 62.94% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on BVS. Craig Hallum boosted their price objective on shares of Bioventus from $15.00 to $16.00 and gave the stock a "buy" rating in a research note on Friday, March 6th. Barrington Research lifted their target price on shares of Bioventus from $13.00 to $14.00 and gave the company an "outperform" rating in a report on Friday, March 6th. Weiss Ratings reissued a "hold (c-)" rating on shares of Bioventus in a research report on Monday, December 29th. Finally, Cantor Fitzgerald upgraded Bioventus to a "strong-buy" rating in a research note on Wednesday, March 4th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $14.25.

Insider Buying and Selling at Bioventus

In related news, Director Michelle Mcmurry-Heath sold 12,000 shares of the business's stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total value of $105,480.00. Following the completion of the transaction, the director directly owned 44,997 shares in the company, valued at $395,523.63. The trade was a 21.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 33.00% of the stock is owned by company insiders.

Bioventus Stock Performance

Shares of Bioventus stock opened at $8.62 on Monday. Bioventus Inc. has a 1 year low of $5.81 and a 1 year high of $10.13. The firm's 50-day moving average is $8.25 and its 200 day moving average is $7.55. The stock has a market cap of $716.75 million, a price-to-earnings ratio of 26.12 and a beta of 0.78. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.70 and a quick ratio of 1.19.

Bioventus (NASDAQ:BVS - Get Free Report) last released its quarterly earnings data on Thursday, March 5th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $0.02. The business had revenue of $157.90 million during the quarter. Bioventus had a net margin of 4.00% and a return on equity of 28.88%. Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.